Pfizer - 25년 1분기 실적발표 (1Q25 Earnings)

Q1-2025-PFE-Earnings-Release-FINAL.pdf

0.20MB

Q1-2025-Earnings-Charts-FINAL.pdf

1.81MB

 
2025-04-29 Pfizer 25년 1분기 실적발표

Albert Bourla CEO의 Prepared Remarks에서 danuglipron 관련 발언:
Our danuglipron announcement earlier this month demonstrates our commitment to this approach. Discontinuing the development of danuglipron, one of the candidates in our obesity portfolio, was the right decision for the company.
 
Going forward, we are committed to building our cardiometabolic pipeline, including in obesity, by advancing internal programs such as our GIPR antagonist and pursuing external opportunities that could include partnerships or acquisitions. We will continue to be disciplined as we move through key decision points for our pipeline.
 
We believe we have the potential to address significant patient need with differentiated approaches that focus on supporting optimal weight management and related conditions. We will work on potential medicines and combination regimens that could be more accessible, better tolerated, easier to dose and more effective in supporting the right effects on body composition and muscle mass.
 
external opportunites : partnerships & acquisitions
Press 발표 이후부터 VKTX, GPCR, MTSR 오르기 시작해서 주가 흐름이 좋았음.

어제는 좋았지만, 1년동안 다들 좋지 않았던 주가 흐름.
최근 Obesity 관련하면 MTSR가 VKTX가 더 강한 모습. 시가총액이 VKTX > MTSR 이기도 하지만
 
Q&A session에서 나왔던 Obesity, Danuglipron 관련 질문들:
 

Evan Seigerman
And I don't want to touch on the reasons for the danu discontinuation. But I more want to look forward, as you think about a potential obesity asset, what are some key aspects of the profile that you're looking for, either from an internal perspective or potentially externally.
Dr. Albert Bourla
Let's start with Chris and then go to Andrew.
Chris Boshoff
Thanks very much. Thanks for the question. Yes, as Albert has stated, danuglipron was the right decision for Pfizer based on totality of data -- and as we said previously, a single asymptomatic participant in a dose optimization study with rapid dose titration experience a potential drug-induced liver injury, which recovered rapidly after treatment discontinuation.
Although we're not 100% sure, this is due to danuglipron. The risk was high enough for us to discontinue the program while still being committed to obesity and employing our global resources for other opportunities. Cardiovascular metabolic is one of our core strategies within internal medicine, an area with significant remaining unmet need. And just a reminder, for obesity alone up to 60% of patients discontinued current approved medicines after 24 months.
We will continue to apply our global capabilities to advance our pipeline of differentiated oral medicines, including our oral GIPR antagonist currently in Phase 2 and advancing our preclinical portfolio to the clinic.
We believe the future will be more fragmented based on differentiated or unique combinations with an emphasis on tolerability, accessibility and convenience. The future will also become more personalized based on combinations addressing specific diseases associated with obesity and with metabolic dysfunction, including neurology, cardiovascular and respiratory.
 
 
Asad Haider
GIP antagonist 관련 질문
Chris Boshoff
Oral small molecule GIPR antagonist was discovered in-house. It's potentially person class oral small molecule GIPR antagonist. And the Phase 2 study is now ongoing. This is a study in obesity in combination with liraglutide with the GLP-1. The PCD is listed on clinicaltrials.gov at the end of 2025. So, expect beginning 2026 potential data, if the data positive in the Phase 2 study, then it could be a potential to be a using combinations to drive weight loss, both with internal or external opportunities.
 
이제 PFE에 남은 Obesity 파이프라은
PF-07976016 (GIPR antagonist)

Danuglipron 병용 하려던 임상은 중단될테고,
Obesity 임상 2상은 결과가 어떻게 나올지 궁금. Q&A session 답변 보니 liraglutide랑 병용을 하는 듯 싶음.
(지금 와서 ligraglutide랑 왜 병용을 하는지 모르겠네? semaglutide라도 해야되는거 아닌가?)
 
PF-06954522 GLP-1 small molecule이 존재하기는 하는데 실적발표 자료에는 표기가 안되어 있음.

Pfizer Pipeline에는 아직 포함되어 있음. 정보가 많이 없음.

clinicaltrials.gov 검색하면 임상시험 3개 정도 나오는데 상당히 early.
danuglipron 대신에 앞으로 PF-06954522에 집중할지 모르겠네
 
Obesity/Cardiometabolic 분야를 계속 하고 싶다고 하면
미국 상장사를 인수할 것인가? 아니면 중국에서 물질을 사올것인가???
이전에 PFE가 NASH/MASH 관심 많았던걸 생각하면, VKTX 사는것도 나쁘지 않을것 같은데
소문만 무성하고 인수는 결국 안나왔고 이제 나올 것이다?
만약에 VKTX를 실제 인수하더라도 Oral Formulation 임상 2상 결과를 보고 하려나?